Trust Signals
Key Takeaways
- Tirzepatide contains exactly one peptide: a synthetic 39-amino-acid dual agonist, not a blend of separate compounds.
- Its backbone is built on the native GIP sequence, with deliberate modifications that confer GLP-1 receptor binding.
- A C18 fatty diacid chain attached at lysine position 20 extends the half-life to roughly 5 days, enabling once-weekly dosing.
- In SURMOUNT-1 (n=2,539), the 15 mg dose produced approximately 20.9% mean body weight reduction at 72 weeks vs. 3.1% for placebo, the highest figure recorded in a non-surgical weight-loss RCT to date.
- Compounded tirzepatide is intended to replicate this same molecule but has no FDA bioequivalence requirement and no standardized purity verification for consumer-facing products.
What Peptides Are in Tirzepatide? (Direct Answer)
Tirzepatide is a single synthetic peptide. It is a 39-amino-acid molecule engineered to activate both the GLP-1 receptor and the GIP receptor simultaneously. There is no second peptide, no blend, and no proprietary mix. The entire clinical effect comes from this one dual-agonist molecule plus its fatty acid modification that extends its duration of action.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
What Is the Exact Structure of Tirzepatide's Peptide?
Tirzepatide's 39-amino-acid chain is built on the scaffold of native human GIP (glucose-dependent insulinotropic polypeptide). Eli Lilly chemists introduced amino acid substitutions at multiple positions to generate meaningful affinity for the GLP-1 receptor, which native GIP does not activate to any appreciable degree. The result is a single molecule that holds measurable agonist activity at both receptors simultaneously.
At lysine at position 20, a gamma-glutamic acid linker connects a C18 fatty diacid moiety to the peptide chain. This fatty acid modification allows reversible binding to circulating albumin, which is the structural reason the molecule stays active in the body for approximately 5 days per dose rather than minutes, which is the fate of native GLP-1 or GIP in the bloodstream. The FDA-approved product (Mounjaro, Zepbound) is delivered as a subcutaneous injection in a prefilled autoinjector at doses of 2.5, 5, 7.5, 10, 12.5, or 15 mg weekly.
Why Does Tirzepatide Target Two Receptors Instead of One?
GLP-1 receptor activation suppresses appetite through hypothalamic signaling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. GIP receptor activation also stimulates insulin secretion and is thought to enhance adipocyte lipolysis and energy expenditure, though the precise contribution of GIP agonism to human weight loss remains an active research question.
The working hypothesis, supported by the SURMOUNT and SURPASS trial series, is that the two receptor pathways contribute additive or synergistic effects on caloric intake and metabolic rate. Notably, the GIP receptor may actually counteract the nausea that GLP-1 agonism can produce at high doses, which could partly explain why tirzepatide achieves greater weight loss at equivalent or better tolerability compared to GLP-1 monotherapy in head-to-head data. This is a mechanistic hypothesis grounded in preclinical and pharmacokinetic data, not a definitively proven causal chain in humans.
What Does the Evidence Actually Show? (Evidence Ledger)
| Claim | Best Evidence Type | Key Data Point | Confidence |
|---|---|---|---|
| Tirzepatide activates both GLP-1R and GIPR | In vitro receptor binding studies, confirmed in humans via PK/PD modeling | Dual agonism confirmed in FDA pharmacology review for Mounjaro NDA | High |
| ~20.9% mean weight loss at 15 mg in adults without diabetes | Phase 3 RCT (SURMOUNT-1, n=2,539, 72 weeks) | Jastreboff et al., NEJM 2022 | High |
| Half-life approximately 5 days enabling weekly dosing | Phase 1 PK studies cited in FDA label | Mounjaro US Prescribing Information, 2022 | High |
| Tirzepatide superior to semaglutide 1 mg for HbA1c reduction | Phase 3 RCT (SURPASS-2, n=1,879, 40 weeks) | Frías et al., NEJM 2021 | High |
| Tirzepatide superior to semaglutide 2.4 mg for weight loss | Phase 3 RCT (SURMOUNT-5, n=741, 72 weeks) | Eli Lilly press release and NEJM 2025 publication | High |
| GIP agonism reduces nausea vs. GLP-1 alone | Animal studies, mechanistic inference from human tolerability data | Preclinical rodent data; no dedicated human RCT isolating this effect | Low |
| Thyroid C-cell tumor risk in humans | Rodent carcinogenicity studies; no human outcome data | FDA boxed warning based on rodent data; human relevance unknown | Very Low (human relevance unproven) |
| Compounded tirzepatide is bioequivalent to branded product | No published human bioequivalence data for compounded versions | No studies identified | Very Low |
What Most Pages Get Wrong About Tirzepatide's Composition
A second omission: most pages ignore the fact that native GIP, when given to individuals with obesity, does not reliably reduce appetite or body weight. Tirzepatide's GIP activity appears to work differently from what infusing native GIP would do, possibly because the modified molecule interacts with the receptor in a distinct conformational way. The mechanism at the GIP receptor for weight loss in humans is genuinely not fully understood as of mid-2026, and any page claiming certainty here is overstating the evidence.
Third omission: the fatty acid chain. The C18 diacid moiety at position 20 is not a filler or a manufacturing artifact. It is the reason the drug works as a weekly injection. Without it, the peptide backbone would be cleared by dipeptidyl peptidase-4 (DPP-4) and renal filtration within minutes to hours, exactly as native GLP-1 is.
Why the Fatty Acid Chain Is Not Cosmetic: The Chemistry Behind Once-Weekly Dosing
Unmodified peptides of this size face two primary clearance mechanisms in the body: enzymatic degradation by DPP-4 (which cleaves at the N-terminus of GLP-1 family peptides) and renal filtration, since the molecule is small enough to pass through the glomerulus.
The C18 fatty diacid chain solves both problems through albumin binding. Albumin is a large plasma protein (molecular weight roughly 66,500 Da) that cannot pass through the glomerular filter. When tirzepatide binds albumin non-covalently through its fatty acid moiety, it is effectively shielded from renal clearance because the complex is too large to filter. Albumin binding also physically obstructs DPP-4 access to the peptide chain's vulnerable cleavage sites. The binding is reversible, meaning free tirzepatide is always in equilibrium with albumin-bound tirzepatide, providing a sustained-release depot in the bloodstream.
This is the same general strategy used by semaglutide (C18 diacid via a linker at lysine 26 of the GLP-1 backbone) and liraglutide (C16 fatty acid, shorter half-life of roughly 13 hours, requiring daily dosing). The longer the carbon chain and the more branched or diacid the structure, the tighter the albumin binding and the longer the half-life. This is why you cannot simply substitute a shorter-chain fatty acid at synthesis and expect the same once-weekly pharmacokinetics.
Tirzepatide vs. Semaglutide: Honest Head-to-Head
| Attribute | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Ozempic/Wegovy) |
|---|---|---|
| Peptide length | 39 amino acids | 34 amino acids (GLP-1 analog) |
| Receptor targets | GLP-1R and GIPR (dual agonist) | GLP-1R only |
| Half-life | Approximately 5 days | Approximately 7 days |
| Dosing frequency | Once weekly | Once weekly |
| Weight loss (best phase 3 dose) | Approximately 20.9% at 15 mg (SURMOUNT-1) | Approximately 14.9% at 2.4 mg (STEP-1, Wilding et al. NEJM 2021) |
| Direct RCT comparison for weight loss | Tirzepatide superior to semaglutide 2.4 mg in SURMOUNT-5 (2025) | Loses to tirzepatide at equivalent weekly dose in head-to-head |
| HbA1c reduction in T2D | Tirzepatide superior to semaglutide 1 mg (SURPASS-2) | Effective but numerically inferior in SURPASS-2 |
| Cardiovascular outcome data | SURMOUNT-MMO ongoing; no finalized MACE reduction label claim as of mid-2026 | SELECT trial (2023): 20% MACE reduction vs. placebo in adults with CVD |
| Where semaglutide wins | No finalized CV outcome trial for tirzepatide weight indication yet | Stronger CV outcome evidence base; longer market history |
| GI side effects | Similar profile; possibly slightly better tolerated at equivalent efficacy doses | Well-characterized nausea, vomiting, diarrhea |
Compounded Tirzepatide: Label Literacy and What to Verify
During the FDA shortage period for branded tirzepatide, compounding pharmacies produced tirzepatide base and tirzepatide salt (commonly the acetate or hydrochloride salt) under 503A or 503B compounding authority. The FDA declared the shortage resolved for Mounjaro and Zepbound doses in early 2025 and moved to restrict most compounding. The regulatory status changes rapidly; verify current FDA guidance before sourcing any compounded version.
If evaluating a compounded tirzepatide product, here is what the COA (certificate of analysis) should show:
| Parameter | What to Look For | Why It Matters |
|---|---|---|
| Identity (HPLC or mass spec) | Molecular weight matching tirzepatide free base or stated salt form, with retention time comparison to reference standard | Confirms you have the correct 39-amino-acid sequence with fatty acid chain, not a truncated or unmodified analog |
| Purity (%) | Greater than 98% by HPLC for a pharmaceutical-grade product | Peptide synthesis generates sequence-truncated impurities; low purity means unknown biological activity from fragments |
| Endotoxin | Less than 5 EU/kg/dose (USP limit for parenteral use) | Bacterial endotoxin contamination causes fever, inflammation, and sepsis-like reactions even from a sterile-appearing vial |
| Sterility | Pass per USP 71 | Subcutaneous injection of a non-sterile product carries direct infection risk |
| Concentration verified | Stated mg/mL confirmed by quantitative HPLC, not just gravimetric fill | Gravimetric filling of lyophilized powder introduces weight error that translates directly to dosing error |
What Are the Main Side Effects and Boxed Warning?
The most common adverse events in SURMOUNT-1 were gastrointestinal: nausea (affecting a majority of participants at some point during dose escalation), diarrhea, vomiting, and constipation. These effects are most pronounced during the first weeks at each new dose level and typically diminish once steady state is reached. The standard escalation protocol (starting at 2.5 mg and increasing by 2.5 mg every 4 weeks) exists specifically to reduce this burden.
The FDA boxed warning covers thyroid C-cell tumors. This warning is based on rodent carcinogenicity studies where GLP-1 receptor agonists produced C-cell hyperplasia and tumors. The human relevance of this finding is currently unknown, and the FDA acknowledges the difference in GLP-1 receptor expression in rodent vs. human thyroid tissue. Tirzepatide carries the same class warning as semaglutide and liraglutide. Pancreatitis, acute kidney injury (usually secondary to dehydration from GI effects), and hypoglycemia (primarily in people also taking insulin or sulfonylureas) are additional labeled risks.
FAQ
What peptides are in tirzepatide?
Tirzepatide contains exactly one synthetic peptide: a 39-amino-acid molecule engineered to act as a dual agonist at both the GLP-1 receptor and the GIP receptor. It is not a blend of multiple peptides.
Is tirzepatide the same as semaglutide?
No. Semaglutide is a 34-amino-acid GLP-1 receptor agonist only. Tirzepatide is a 39-amino-acid molecule that activates both GLP-1 and GIP receptors. In SURMOUNT-5, tirzepatide produced greater mean weight loss than semaglutide 2.4 mg in a direct randomized comparison.
What is the amino acid sequence backbone of tirzepatide based on?
Tirzepatide's backbone is based on the native GIP sequence, with modifications at key positions to enable GLP-1 receptor binding. A C18 fatty diacid chain is attached via a linker to lysine at position 20 to extend the half-life to roughly 5 days.
Does tirzepatide also activate the glucagon receptor?
No. Tirzepatide is selective for GLP-1 and GIP receptors. It does not meaningfully activate the glucagon receptor at therapeutic concentrations. Triple agonist molecules targeting glucagon as well are in separate development pipelines.
How long does tirzepatide stay active in the body?
Tirzepatide has an elimination half-life of approximately 5 days, which is why it is dosed once weekly. This half-life is achieved through albumin binding via its fatty acid chain, which slows renal clearance and protects against peptide degradation.
What is the difference between GLP-1 and GIP, the two receptors tirzepatide targets?
GLP-1 suppresses appetite, slows gastric emptying, and stimulates insulin secretion. GIP also stimulates insulin secretion and may enhance fat metabolism and energy expenditure. Activating both simultaneously appears to produce additive or synergistic effects on weight loss, though the exact contribution of GIP agonism remains under investigation.
How much weight loss does tirzepatide produce in clinical trials?
In SURMOUNT-1 (2,539 adults without diabetes), the 15 mg dose produced a mean body weight reduction of approximately 20.9% at 72 weeks compared to 3.1% for placebo. This is the highest figure recorded for a non-surgical weight-loss intervention in a phase 3 RCT to date.
Are compounded versions of tirzepatide the same peptide?
Compounded tirzepatide is intended to replicate the same 39-amino-acid peptide, but compounded products are not FDA-approved and are not required to demonstrate bioequivalence. Purity, sterility, and lipid-chain fidelity vary by compounding pharmacy and are not independently verified for most products sold online.
Can tirzepatide be taken orally?
No approved oral form of tirzepatide exists as of mid-2026. The peptide is degraded by gastrointestinal proteases before meaningful absorption can occur. The approved and compounded forms are subcutaneous injections.
What are the main side effects of tirzepatide?
The most common side effects in SURMOUNT-1 are gastrointestinal: nausea, diarrhea, vomiting, and constipation, occurring most frequently during dose escalation. Serious events including pancreatitis and a theoretical thyroid C-cell risk carry FDA boxed warning language, though the thyroid risk is based on rodent data and human relevance is not established.
Is tirzepatide a peptide or a small molecule drug?
Tirzepatide is a peptide drug, not a small molecule. Its 39-amino-acid chain with a fatty acid modification puts it in the same general class as GLP-1 receptor agonist peptides such as semaglutide and liraglutide.
Sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1)
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515. (SURPASS-2)
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. (STEP-1)
- Eli Lilly and Company. Mounjaro (tirzepatide) US Prescribing Information. 2022. Available via FDA Drugs@FDA.
- Eli Lilly and Company. SURMOUNT-5 trial results. New England Journal of Medicine. 2025. (Tirzepatide vs. semaglutide 2.4 mg head-to-head)
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14.
- Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370-7380. (Basis for fatty acid modification comparison)
- US FDA. Mounjaro (tirzepatide): drug approval package and pharmacology review. Available via FDA Drugs@FDA. 2022.
- US FDA. Compounding of tirzepatide: shortage status notifications. FDA.gov. 2024-2025.
- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism. 2018;20(Suppl 1):5-21.